Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Surufatinib + Tislelizumab for Biliary Tract Cancer
NCT06134193Phase 2Unknown
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and tislelizumab in biliary tract cancer (BTC). Primary endpoint: Progression Free Survival at 18 months. Status: unknown.
02
Drugs
surufatinibtislelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06134193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134193.